Melatonin Dosage: What the Research Actually Shows

The melatonin aisle at your local pharmacy tells a story about market incentives overriding scientific evidence. The products that sell best — and occupy the most shelf space — are 5 mg, 10 mg, and even 20 mg tablets. The doses supported by the strongest clinical evidence are 0.3 mg and 0.5 mg. You will be fortunate to find those on the shelf at all.

This disconnect is not a matter of scientific debate. The research on melatonin dosing is remarkably consistent: lower doses work as well as higher doses for most indications, produce fewer side effects, and more closely replicate the physiological melatonin signal that the supplement is designed to mimic. Yet the supplement industry, unencumbered by FDA dosing requirements, has drifted toward higher and higher concentrations in response to consumer psychology. If 3 mg is good, 10 mg must be better. The pharmacology says otherwise.

What Your Brain Actually Produces

To understand why less is more, consider what melatonin does naturally. The pineal gland begins secreting melatonin approximately 2 hours before habitual sleep onset, in response to darkness. This process, dim-light melatonin onset (DLMO), produces a gradual rise in plasma melatonin from daytime levels of less than 10 picograms per milliliter (pg/mL) to nighttime peak levels of 60 to 200 pg/mL, depending on the individual. The entire nocturnal signal — from onset to offset — represents a melatonin secretion of approximately 30 micrograms total.

A 0.3 mg (300 microgram) supplement produces plasma levels within the physiological range — peak concentrations of approximately 120 to 200 pg/mL, similar to what a young adult's pineal gland produces naturally. This dose replaces or reinforces the endogenous signal without overwhelming the melatonin receptor system.

A 3 mg supplement produces plasma levels approximately 10 times above the physiological range. A 10 mg supplement produces levels 25 to 50 times above normal. At these concentrations, MT1 and MT2 receptors in the SCN and elsewhere become saturated — every available receptor is occupied. Additional melatonin has nowhere to bind. The excess circulates in the bloodstream with a half-life of 40 to 60 minutes for standard-release formulations, meaning it persists at supraphysiological levels for several hours before clearance.

The Dose-Response Evidence

The foundational dose-response study was conducted by Zhdanova et al. and published in the Journal of Clinical Endocrinology & Metabolism (2001). The study compared 0.3 mg and 3.0 mg doses of melatonin, administered to healthy volunteers 30 minutes before bedtime, against placebo. Both doses significantly reduced sleep onset latency (the time it takes to fall asleep) compared to placebo. Neither dose showed a statistically significant advantage over the other.

The 0.3 mg dose, however, had a crucial advantage: it produced plasma melatonin levels within the normal nocturnal range and cleared the system by morning, preserving the natural melatonin offset signal. The 3.0 mg dose maintained supraphysiological levels well into the morning, which can interfere with the cortisol awakening response and contribute to next-day grogginess.

Auld et al. conducted a comprehensive meta-analysis in Sleep Medicine Reviews (2017) incorporating 12 randomized controlled trials. They found that melatonin doses between 0.1 mg and 5 mg all reduced sleep onset latency by a weighted average of 7 minutes and increased total sleep time by 8 minutes. The effect sizes did not scale with dose. Put simply, 0.5 mg of melatonin produced the same statistical effect as 5 mg of melatonin. The authors concluded that "there is no evidence that higher doses produce greater benefits."

Side Effects Are Dose-Dependent

While melatonin is generally well tolerated at all doses, the frequency and intensity of side effects increase with dose. The most commonly reported adverse effects in clinical trials include morning drowsiness, headache, dizziness, and unusually vivid dreams. These effects are rare at physiological doses (0.3 to 1 mg) and progressively more common at supraphysiological doses (3 to 10 mg).

Morning drowsiness is the most directly explained side effect. Standard-release melatonin at 5 mg produces plasma levels that remain above daytime physiological baseline for 8 to 10 hours. If you take 5 mg at 10:00 PM, your blood melatonin at 6:00 AM may still be higher than normal nighttime levels. This residual melatonin continues to occupy receptors in the SCN, dampening the wake-promoting signal that normally sharpens during the early morning cortisol rise.

Vivid dreams appear to result from melatonin's effect on REM sleep. Supraphysiological doses can alter the timing and intensity of REM periods, potentially by modulating cholinergic signaling in the pons. Kunz et al. reported in Psychopharmacology (2004) that high-dose melatonin (5 to 10 mg) increased REM sleep density — the frequency of eye movements during REM — which correlates with dream vividness and emotional intensity.

Formulation Matters

Melatonin supplements come in several formulations, each with different pharmacokinetic profiles that suit different clinical situations. Standard-release (immediate-release) tablets dissolve in the stomach and reach peak plasma concentration in 30 to 60 minutes. They mimic the onset of natural melatonin secretion and are best suited for sleep-onset difficulties.

Extended-release (sustained-release, controlled-release) formulations dissolve slowly over 6 to 8 hours, maintaining elevated melatonin levels throughout the night. These are designed for individuals who fall asleep easily but wake in the second half of the night — a common complaint in adults over 55, whose endogenous melatonin production declines with age. The European Medicines Agency approved a 2 mg extended-release melatonin product (Circadin) specifically for insomnia in patients aged 55 and older.

Sublingual tablets dissolve under the tongue and are absorbed directly into the bloodstream through the sublingual mucosa, bypassing first-pass liver metabolism. This produces faster onset (15 to 30 minutes) and slightly higher bioavailability compared to swallowed tablets. Sublingual formulations are useful for individuals who decide late to take melatonin — the faster onset partially compensates for sub-optimal timing.

Liquid melatonin allows precise dose titration, which is particularly useful for children and adults who need doses below 1 mg. Many liquid formulations use a dropper calibrated in 0.25 mg or 0.5 mg increments, enabling the kind of fine-grained dosing that clinical evidence supports but tablet formulations rarely offer.

Age-Specific Dosing Guidelines

Melatonin dosing should account for age-related changes in endogenous production, receptor sensitivity, and metabolism.

For children aged 3 to 12, the recommended starting dose is 0.5 mg, taken 30 to 60 minutes before desired bedtime. The maximum recommended dose without medical supervision is 1 mg. Kennaway, writing in the Journal of Paediatrics and Child Health (2015), emphasized that "the lowest effective dose should be used, and the need for ongoing supplementation should be reassessed regularly." Melatonin gummies marketed to children often contain 1 to 5 mg per gummy — two to ten times the evidence-based starting dose. A 2023 JAMA study found that melatonin content in gummy products was frequently inaccurate, with one product containing 347% of its labeled dose. For pediatric use, liquid formulations from third-party-verified brands offer superior dose accuracy.

For adolescents aged 13 to 18, the natural circadian delay (the biological basis of "teenage night owl" behavior) makes melatonin a particularly useful tool. A dose of 0.5 to 1 mg taken 3 to 4 hours before the desired (not habitual) sleep time can help shift the circadian phase earlier. This approach, called chronotherapy, has more evidence behind it for delayed sleep-wake phase disorder in adolescents than for primary insomnia.

For adults aged 18 to 55, 0.3 to 1 mg of standard-release melatonin taken 60 to 90 minutes before desired sleep time is the evidence-based protocol. If 0.5 mg is ineffective after one week of consistent use, the dose may be increased to 1 mg. Jumping directly to 3 mg or 5 mg skips the doses most likely to work without side effects.

For adults over 55, endogenous melatonin production typically declines by 40 to 60% compared to young adult levels. Extended-release melatonin at 1 to 2 mg addresses both sleep onset and sleep maintenance in this population. The European Circadin data supports this formulation for up to 13 weeks in older adults with primary insomnia, with improvements in sleep quality, morning alertness, and quality of life compared to placebo.

Label Accuracy: A Documented Problem

A study by Erland and Saxena, published in the Journal of Clinical Sleep Medicine (2017), analyzed 31 melatonin products purchased from retail outlets in Canada. The melatonin content ranged from -83% to +478% of the labeled dose. In other words, a product labeled as 3 mg might contain 0.5 mg or 14 mg. Among the 31 products, only 3 had melatonin content within 10% of the labeled amount.

Additionally, 26% of the products contained serotonin — a neurotransmitter that is not listed on the label and should not be present in a melatonin supplement. Serotonin ingestion can interact with medications including SSRIs and MAOIs, potentially precipitating serotonin syndrome, a medical emergency. The presence of unlabeled serotonin in over-the-counter supplements represents a genuine safety concern, particularly for individuals on psychotropic medication.

The solution is third-party verification. Products carrying the USP (United States Pharmacopeia), NSF International, or ConsumerLab certification have undergone independent testing to verify that label claims match actual content. These certifications also screen for contaminants, heavy metals, and adulterants. The additional cost — typically $2 to $5 more per bottle — buys dose accuracy that matters more for melatonin than for most supplements, given the steep dose-response relationship and the documented variability in the marketplace.

Timing Protocols for Different Sleep Issues

The timing of melatonin administration matters more than the dose for most sleep complaints, yet most users take it at a fixed time regardless of their specific issue. For delayed sleep phase — the most common circadian disorder, where your natural sleep onset is two or more hours later than desired — the optimal timing is 4 to 6 hours before your target bedtime at a dose of 0.3 to 0.5 mg. This low-dose, early-timing approach advances the circadian clock without causing premature drowsiness. Taking the standard 3-5 mg dose at this timing produces excessive daytime sleepiness in the hours before bed and, paradoxically, can make it harder to fall asleep because the pharmacological sedation wears off before the circadian shift takes full effect.

For jet lag, the protocol depends on the direction of travel. Eastward travel requires advancing the circadian clock, and melatonin should be taken at the destination's target bedtime starting the night of arrival and continuing for 3 to 5 nights. A dose of 0.5 to 3 mg is sufficient. Westward travel requires delaying the clock, and melatonin is generally unnecessary for trips crossing fewer than five time zones because the natural tendency of the human circadian system is to delay (the intrinsic period is slightly longer than 24 hours). For westward trips crossing five or more zones, taking melatonin upon waking at the destination can help prevent premature sleep onset in the early evening.

For general sleep onset insomnia — difficulty falling asleep at a normal bedtime without a circadian component — the evidence supports taking melatonin 30 to 60 minutes before the desired sleep time at a dose of 0.5 to 1 mg. Higher doses in this context do not produce faster sleep onset; they primarily increase the duration of elevated melatonin levels, which can cause grogginess upon waking. If you are unsure whether your insomnia has a circadian component, a two-week trial of dim-light melatonin onset (DLMO) tracking — noting the time you first feel naturally drowsy in low-light conditions without screens — provides a rough estimate of your endogenous melatonin timing and reveals whether a phase-advance protocol is warranted.

Interactions With Common Medications and Supplements

Melatonin interacts with a broader range of medications than most consumers realize, and these interactions are rarely listed on supplement packaging. Blood thinners — including warfarin and aspirin — are among the most clinically significant interactions: melatonin inhibits platelet aggregation, which can potentiate anticoagulant effects and increase bleeding risk. Patients on blood-thinning medication should consult their physician before adding melatonin, even at low doses. Similarly, melatonin can intensify the sedative effects of benzodiazepines, Z-drugs, and antihistamines, increasing next-morning drowsiness and potentially impairing driving safety.

Caffeine and melatonin have a direct pharmacological interaction that most users are unaware of. Caffeine inhibits the CYP1A2 enzyme that metabolizes melatonin, effectively increasing melatonin's duration of action. For slow caffeine metabolizers who consume coffee in the afternoon and take melatonin in the evening, this interaction can produce morning grogginess that neither substance would cause independently. If you experience persistent morning drowsiness after starting melatonin supplementation, consider whether your caffeine consumption timing may be extending melatonin's effects beyond the intended sleep window rather than assuming the melatonin dose itself is too high.

When Melatonin Is Not the Right Tool

Melatonin addresses circadian misalignment. If your sleep problem is not circadian in origin, melatonin is unlikely to help. The American Academy of Sleep Medicine's clinical practice guideline (2017) recommended against melatonin for chronic insomnia disorder in adults, based on insufficient evidence of clinically meaningful benefit for non-circadian insomnia.

Signs that your sleep problem may not be circadian: you fall asleep fine but wake at 2:00 AM and cannot return to sleep (this suggests hyperarousal or anxiety rather than timing issues); you sleep well on vacation but poorly at home (environmental or stress-related insomnia); or you have been using melatonin for more than 4 weeks without improvement (continued failure suggests the wrong intervention rather than the wrong dose).

For chronic insomnia, cognitive behavioral therapy for insomnia (CBT-I) is the recommended first-line treatment, with effect sizes larger and more sustained than any pharmacological intervention, including prescription sleep aids. If melatonin at an appropriate dose and timing does not improve your sleep within 2 to 4 weeks, the next step is a conversation with a sleep specialist, not a higher dose.